Sangamo Therapeutics, Inc.
SGMO
$0.14
$0.000.22%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2,348.88% | -96.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2,348.88% | -96.83% | |||
| Cost of Revenue | 11.71% | 3.91% | |||
| Gross Profit | 37.56% | -213.98% | |||
| SG&A Expenses | -2.93% | -11.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.47% | -0.07% | |||
| Operating Income | 29.77% | -99.12% | |||
| Income Before Tax | -8.21% | -75.82% | |||
| Income Tax Expenses | -243.48% | -696.30% | |||
| Earnings from Continuing Operations | -7.13% | -74.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.13% | -74.77% | |||
| EBIT | 29.77% | -99.12% | |||
| EBITDA | 30.54% | -104.98% | |||
| EPS Basic | 3.48% | -47.56% | |||
| Normalized Basic EPS | 36.48% | -48.66% | |||
| EPS Diluted | 3.48% | -47.56% | |||
| Normalized Diluted EPS | 36.48% | -48.66% | |||
| Average Basic Shares Outstanding | 11.00% | 18.42% | |||
| Average Diluted Shares Outstanding | 11.00% | 18.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||